source
- Replimune’s twice-rejected melanoma drug prevails in FDA adcommFollowing a pair of FDA rejections for its melanoma drug, Replimune’s fortunes flipped today after an advisory committee voted 10 to 3 in favor of the candidate’s effectiveness.Fierce Biotech · 4h ago↗ source
- Daiichi’s pipeline falls behind rivals as cash flow nears peak: analystsWith Enhertu and Datroway hitting their peak revenue and rivals flowing into the antibody-drug conjugate space, Jefferies cuts expectations for Daiichi Sankyo.BioSpace · 9h ago↗ source
- Relation promises 'transformationally different success rates' in expanded AI pact with GSKGSK is set to pay Relation Therapeutics up to $110 million to expand their existing partnership to use AI modeling for drug discovery. Under the Thursday deal, Relation will build a ...